Cellectis CLLS
NASDAQ CLLS
$0.97 -0.02 (-2.17%)
At close: Oct 21, 2026 · 4:00 PM EDT

Cellectis (CLLS) Current Deferred Tax Assets (2015 - 2024)

Updated

Cellectis (CLLS) reported Current Deferred Tax Assets of $710,000 for Q2 2024, up 73.6% from the prior quarter.

Analysis

Cellectis (CLLS) Current Deferred Tax Assets (2015 - 2024) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,136.97 Bn 1,105.55 Bn 19.71 Bn
2 Johnson & Johnson 619.72 Bn 538.25 Bn 17.26 Bn
3 AbbVie 503.40 Bn 476.52 Bn 12.70 Bn
4 Merck 370.15 Bn 324.53 Bn 12.21 Bn
5 Novartis Ag 298.64 Bn 262.63 Bn 11.24 Bn
6 Astrazeneca 261.07 Bn 234.76 Bn 12.86 Bn
7 Amgen 237.00 Bn 192.40 Bn 7.24 Bn
8 Gilead Sciences 191.24 Bn 165.43 Bn 6.22 Bn
9 Pfizer 170.31 Bn 116.96 Bn 10.94 Bn
10 Cellectis 98.28 Mn -655.11 Mn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2024 710,000.00
Mar 31, 2024 409,000.00
Dec 31, 2016 -43.03 Mn
Dec 31, 2015 -38.06 Mn
API Access

Cellectis Current Deferred Tax Assets API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=current-deferred-tax-assets&ticker=CLLS&period=max&api_key=YOUR_API_KEY